Abstract Background Starting in November 2020, the US Food and Drug Administration
(FDA) has issued Emergency Use Authorizations (EUAs) for multiple novel virus-neutralizing …

Abstract Background In November 2020, the US Food and Drug Administration (FDA)
provided Emergency Use Authorizations (EUA) for 2 novel virus-neutralizing monoclonal …

Background: Although severe COVID-19 in children is rare, those with certain pre-existing
health conditions are more prone to severe disease. Monoclonal antibodies (mAbs) against …

Monoclonal antibody therapies for COVID-19 have been frequently used in adults, whereas
there are little data regarding the safety or efficacy of monoclonal antibody treatments in …

There is a little data regarding safety or efficacy of monoclonal antibody treatment for mild-to-
moderate COVID-19 in pediatric patients despite it being frequently used in adults. This …

The fast diffusion of the SARS-CoV-2 pandemic have called for an equally rapid evolution of
the therapeutic options. The Human recombinant monoclonal antibodies (mAbs) have …

Multiple antiviral and monoclonal antibody therapies are now available for mild-moderate
COVID-19 in high-risk patients≥ 12 years of age. However, data for the use of these agents …

Objective To identify subgroups likely to benefit from monoclonal antibody and antiviral
therapy by evaluating the relationship between comorbidities and hospitalization among US …

The global spread of COVID-19 has imparted significant economic, medical, and social
burdens. Like adults, children are affected by this pandemic. However, milder clinical …

Methods The Texas Coronavirus Antibody REsponse Survey (Texas CARES) is an ongoing
prospective population-based seroprevalence project designed to assess antibody status …